Letarouilly Jean-Guillaume, Flipo René-Marc, Cortet Bernard, Tournadre Anne, Paccou Julien
University of Lille F-59000 Lille, CHU Lille F-59000 Lille, France; University of Littoral Côte d'Opale F-62200 Boulogne-sur-Mer, France; Marrow Adiposity and Bone Lab - MABLab ULR4490Lille, France.
Department of Rheumatology, University of Lille, CHU Lille, F-59000 Lille, France.
Ther Adv Musculoskelet Dis. 2021 Jun 21;13:1759720X211015006. doi: 10.1177/1759720X211015006. eCollection 2021.
There is growing interest in the alterations in body composition (BC) that accompany rheumatoid arthritis (RA). The purpose of this review is to (i) investigate how BC is currently measured in RA patients, (ii) describe alterations in body composition in RA patients and (iii) evaluate the effect on nutrition, physical training, and treatments; that is, corticosteroids and biologic Disease Modifying Anti-Rheumatic Disease (bDMARDs), on BC in RA patients. The primary-source literature for this review was acquired using PubMed, Scopus and Cochrane database searches for articles published up to March 2021. The Medical Subject Headings (MeSH) terms used were 'Arthritis, Rheumatoid', 'body composition', 'sarcopenia', 'obesity', 'cachexia', 'Absorptiometry, Photon' and 'Electric Impedance'. The titles and abstracts of all articles were reviewed for relevant subjects. Whole-BC measurements were usually performed using dual energy x-ray absorptiometry (DXA) to quantify lean- and fat-mass parameters. In RA patients, lean mass is lower and adiposity is higher than in healthy controls, both in men and women. The prevalence of abnormal BC conditions such as overfat, sarcopenia and sarcopenic obesity is significantly higher in RA patients than in healthy controls; these alterations in BC are observed even at an early stage of the disease. Data on the effect treatments on BC in RA patients are scarce. In the few studies published, (a) creatine supplementation and progressive resistance training induce a slight and temporary increase in lean mass, (b) exposure to corticosteroids induces a gain in fat mass and (c) tumour necrosis factor alpha (TNFα) inhibitors might be associated with a gain in fat mass, while tocilizumab might be associated with a gain in lean mass. The available data clearly demonstrate that alterations in BC occur in RA patients, but data on the effect of treatments, especially bDMARDs, are inconsistent and further studies are needed in this area.
人们对类风湿关节炎(RA)伴发的身体成分(BC)改变越来越感兴趣。本综述的目的是:(i)研究目前如何测量RA患者的身体成分;(ii)描述RA患者身体成分的改变;(iii)评估营养、体育锻炼及治疗(即皮质类固醇和生物性改善病情抗风湿药(bDMARDs))对RA患者身体成分的影响。本综述的主要文献来源是通过检索PubMed、Scopus和Cochrane数据库,查找截至2021年3月发表的文章。使用的医学主题词(MeSH)包括“关节炎,类风湿性”“身体成分”“肌肉减少症”“肥胖症”“恶病质”“光子吸收测定法”和“电阻抗”。对所有文章的标题和摘要进行了相关主题审查。全身身体成分测量通常使用双能X线吸收法(DXA)来量化瘦体重和脂肪量参数。在RA患者中,无论男性还是女性,其瘦体重均低于健康对照,而肥胖程度高于健康对照。RA患者中,诸如脂肪过多、肌肉减少症和肌少症肥胖等异常身体成分状况的患病率显著高于健康对照;这些身体成分的改变在疾病早期即可观察到。关于治疗对RA患者身体成分影响的数据很少。在已发表的少数研究中,(a)补充肌酸和进行渐进性抗阻训练可使瘦体重略有且暂时增加,(b)使用皮质类固醇会导致脂肪量增加,(c)肿瘤坏死因子α(TNFα)抑制剂可能与脂肪量增加有关,而托珠单抗可能与瘦体重增加有关。现有数据清楚地表明,RA患者存在身体成分改变,但关于治疗效果的数据,尤其是bDMARDs的效果,并不一致,该领域需要进一步研究。